Demographic and clinical characteristics
| . | Intensive treatment (n = 36) . | Nonintensive treatment (n = 75) . |
|---|---|---|
| Age, median (range), y | 67.5 (60.5-82.1) | 72.4 (60.6-92.3) |
| Age group, n (%) | ||
| 60-64 | 11 (30.6%) | 12 (16.0%) |
| 65-69 | 12 (33.3%) | 15 (20.0%) |
| 70-74 | 7 (19.4%) | 16 (21.3%) |
| 75-79 | 4 (11.1%) | 15 (20.0%) |
| ≥80 | 2 (5.6%) | 17 (22.7%) |
| Female sex, n (%) | 15 (41.7%) | 22 (29.3%) |
| Race, n (%) | ||
| White | 35 (97.2%) | 65 (86.7%) |
| Black/African American | 0 (0.0%) | 3 (4.0%) |
| Native Hawaiian or Pacific Islander | 0 (0.0%) | 1 (1.3%) |
| Unknown | 1 (2.8%) | 6 (8.0%) |
| Hispanic ethnicity, n (%) | 1 (2.8%) | 0 (0.0%) |
| ECOG PS, n (%) | ||
| 0 | 23 (63.9%) | 29 (38.7%) |
| 1 | 8 (22.2%) | 36 (48.0%) |
| 2 | 4 (11.1%) | 9 (12.0%) |
| Missing | 1 (2.8%) | 1 (1.3%) |
| FLT3, n (%) | ||
| FLT3 ITD | 27 (75.0%) | 1 (1.3%) |
| FLT3 TKD | 9 (25.0%) | 1 (1.3%) |
| No FLT3 gene mutation | 0 (0.0%) | 73 (97.3%) |
| Clinical onset of AML, n (%) | ||
| De novo | 29 (80.6%) | 44 (58.7%) |
| Therapy-related myeloid | 3 (8.3%) | 9 (12.0%) |
| MDS related | 4 (11.1%) | 12 (16.0%) |
| Antecedent hemolytic disorder | 0 (0.0%) | 10 (13.3%) |
| ELN category, n (%) | ||
| Adverse | 2 (5.6%) | 27 (36.0%) |
| Normal/intermediate | 29 (80.6%) | 37 (49.3%) |
| No diagnosis cytogenetics | 5 (13.9%) | 11 (14.7%) |
| Marrow blasts, median (range), %∗ | 57.5 (0.0-96.0) | 10.0 (0.0-91.0) |
| Peripheral WBC count, median (range), ×103/μL† | 13.5 (0.8-343.6) | 3.0 (0.0-212.7) |
| LDH, median (range), U/L | 526.5 (103.0-2813.0) | 234.0 (68.0-1467.0) |
| Creatinine, median (range), mg/dL | 0.9 (0.4-1.7) | 0.9 (0.1-7.0) |
| LVEF, median (range), %‡ | 62.0 (42.0-76.0) | 61.0 (29.0-81.0) |
| . | Intensive treatment (n = 36) . | Nonintensive treatment (n = 75) . |
|---|---|---|
| Age, median (range), y | 67.5 (60.5-82.1) | 72.4 (60.6-92.3) |
| Age group, n (%) | ||
| 60-64 | 11 (30.6%) | 12 (16.0%) |
| 65-69 | 12 (33.3%) | 15 (20.0%) |
| 70-74 | 7 (19.4%) | 16 (21.3%) |
| 75-79 | 4 (11.1%) | 15 (20.0%) |
| ≥80 | 2 (5.6%) | 17 (22.7%) |
| Female sex, n (%) | 15 (41.7%) | 22 (29.3%) |
| Race, n (%) | ||
| White | 35 (97.2%) | 65 (86.7%) |
| Black/African American | 0 (0.0%) | 3 (4.0%) |
| Native Hawaiian or Pacific Islander | 0 (0.0%) | 1 (1.3%) |
| Unknown | 1 (2.8%) | 6 (8.0%) |
| Hispanic ethnicity, n (%) | 1 (2.8%) | 0 (0.0%) |
| ECOG PS, n (%) | ||
| 0 | 23 (63.9%) | 29 (38.7%) |
| 1 | 8 (22.2%) | 36 (48.0%) |
| 2 | 4 (11.1%) | 9 (12.0%) |
| Missing | 1 (2.8%) | 1 (1.3%) |
| FLT3, n (%) | ||
| FLT3 ITD | 27 (75.0%) | 1 (1.3%) |
| FLT3 TKD | 9 (25.0%) | 1 (1.3%) |
| No FLT3 gene mutation | 0 (0.0%) | 73 (97.3%) |
| Clinical onset of AML, n (%) | ||
| De novo | 29 (80.6%) | 44 (58.7%) |
| Therapy-related myeloid | 3 (8.3%) | 9 (12.0%) |
| MDS related | 4 (11.1%) | 12 (16.0%) |
| Antecedent hemolytic disorder | 0 (0.0%) | 10 (13.3%) |
| ELN category, n (%) | ||
| Adverse | 2 (5.6%) | 27 (36.0%) |
| Normal/intermediate | 29 (80.6%) | 37 (49.3%) |
| No diagnosis cytogenetics | 5 (13.9%) | 11 (14.7%) |
| Marrow blasts, median (range), %∗ | 57.5 (0.0-96.0) | 10.0 (0.0-91.0) |
| Peripheral WBC count, median (range), ×103/μL† | 13.5 (0.8-343.6) | 3.0 (0.0-212.7) |
| LDH, median (range), U/L | 526.5 (103.0-2813.0) | 234.0 (68.0-1467.0) |
| Creatinine, median (range), mg/dL | 0.9 (0.4-1.7) | 0.9 (0.1-7.0) |
| LVEF, median (range), %‡ | 62.0 (42.0-76.0) | 61.0 (29.0-81.0) |
ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet (2010); ITD, internal tandem duplication; LDH, lactate dehydrogenase; LVEF, left ventricle ejection fraction; MDS, myelodysplastic syndrome; TKD, tyrosine kinase domain; WBC, white blood cell.
Data available for 62 patients in CALGB 11002.
Data available for 73 patients in CALGB 11002.
Data available for 35 patients in CALGB 11001 and 68 patients in 11002.